Powder: -20°C for 3 years | In solvent: -80°C for 1 year
CCG 203769 (Thiadiazolidinone (TDZD) deriv. 6) is a selective inhibitor of RGS4 with an IC50 of 17 nM for the RGS4-Gαo protein-protein interaction.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 116.00 | |
2 mg | In stock | $ 169.00 | |
5 mg | In stock | $ 289.00 | |
10 mg | In stock | $ 497.00 | |
25 mg | In stock | $ 793.00 | |
50 mg | In stock | $ 1,130.00 | |
100 mg | In stock | $ 1,520.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 318.00 |
Description | CCG 203769 (Thiadiazolidinone (TDZD) deriv. 6) is a selective inhibitor of RGS4 with an IC50 of 17 nM for the RGS4-Gαo protein-protein interaction. |
Targets&IC50 | RGS16:6 μM, RGS8:79 μM, RGS4:17 nM, RGS19:140 nM, GSK3β:5.4 μM |
In vitro | CCG 203769 displays dramatic selectivity (8- to >5000-fold) for RGS4 over other RGS proteins with IC50s of 140 nM, 6 μM, and 79 μM for RGS19, RGS16, and RGS8. CCG 203769 inhibits GSK-3β with an IC50 of 5 μM. CCG 203769 enhances Gαq-dependent cellular Ca2+ signaling in an RGS4-dependent manner and inhibits RGS/Gαo binding in an RGS-selective manner. CCG 203769 also blocks the GTPase accelerating protein (GAP) activity of RGS4. CCG 203769 inhibits the effect of GTP hydrolysis stimulated by RGS4 with an IC50<1 μM in single-turnover and steady-state GTPase experiments[1]. |
In vivo | CCG 203769 (10 mg/kg, i.v.), administered immediately prior to Carbamoylcholine chloride(0.1 mg/kg, i.p.), significantly potentiates the bradycardic effect. CCG 203769 (1-10 mg/kg) reverses the increased hang time caused by raclopride administration in rats. CCG 203769 (0.1-10 mg/kg) reverses the raclopride-induced paw drag in mice[1]. |
Synonyms | 4-butyl-2-ethyl-1,2,4-thiadiazolidine-3,5-dione, RGS4 inhibitor 11b, Thiadiazolidinone (TDZD) deriv. 6 |
Molecular Weight | 202.27 |
Formula | C8H14N2O2S |
CAS No. | 410074-60-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 50 mg/mL (247.2 mM), sonification is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
CCG 203769 410074-60-1 GPCR/G Protein Neuroscience PI3K/Akt/mTOR signaling Stem Cells Dopamine Receptor GSK-3 GTPase CCG203769 CCG-203769 4-butyl-2-ethyl-1,2,4-thiadiazolidine-3,5-dione RGS4 inhibitor 11b Thiadiazolidinone (TDZD) deriv. 6 inhibitor inhibit